Improved Quality of Life, Physical Functioning, and Cancer-Related Fatigue
The most consistently associated outcome with participation in supervised structured exercise programs in cancer survivors is improved quality of life, physical functioning, and cancer-related fatigue (Answer B). This finding is robustly supported by the highest-quality guideline evidence and consistently demonstrated across multiple recent studies.
Evidence from ASCO Guidelines
The 2024 ASCO-Society for Integrative Oncology guideline on fatigue management 1 and the 2022 ASCO guideline on exercise during cancer treatment 2 both establish that exercise interventions consistently demonstrate improvements in:
- Cardiorespiratory fitness
- Reduction in fatigue symptoms
- Quality of life improvements across multiple domains
The 2022 ASCO guideline explicitly states that "the results consistently demonstrate that increasing exercise during treatment improves cardiorespiratory fitness and reduces symptoms such as fatigue" 2. These benefits are documented across different forms of exercise with varying schedules, intensities, and administration methods, indicating the robustness of these outcomes.
Supporting Research Evidence
Multiple 2026 studies corroborate these guideline recommendations:
A community-based program for adolescent and young adult survivors showed significant improvements in predicted VO₂peak, strength measures, physical function, and quality of life across physical, role, and social domains, with decreased fatigue (p < 0.001) 3
An exercise motivation study demonstrated improvements in QoL domains, particularly physical and emotional functioning, with decreased pain and fatigue symptoms 4
The EXCEL study showed significant small to moderate improvements in well-being, fatigue (r = 0.25), and symptom severity, alongside moderate to large improvements in physical function measures 5
Why Other Options Are Incorrect
Option A (Recurrence-free survival): No evidence supports that exercise improves recurrence-free survival across all cancer types regardless of stage. This outcome was not consistently demonstrated in the provided evidence.
Option C (CIPN elimination): The evidence does not support that exercise significantly improves neuropathy symptoms or eliminates chemotherapy-induced peripheral neuropathy in most patients. This is not a consistently reported outcome.
Option D (Treatment adherence only during chemotherapy): While the 2022 ASCO guideline notes that patients whose providers discussed exercise were more likely to engage in physical activity 2, the benefits extend well beyond just treatment adherence during active chemotherapy and include post-treatment survivorship.
Clinical Implications
The 2022 ASCO guideline emphasizes that "oncology providers should include assessment of exercise behaviors and recommendations to exercise as a part of oncology visits" 2. The evidence demonstrates few adverse events when exercise is supervised by professionals, making this a safe and effective intervention for improving the triad of quality of life, physical functioning, and fatigue—the most consistently documented benefits across the cancer survivorship literature.